智通财经APP获悉，据港交所1月26日披露，上海奥科达医药科技股份有限公司(简称：奥科达医药)向港交所主板递交上市申请书，招商证券国际、建银国际 为其联席保荐人。 公司简介 招股书显示，奥科达为一家研发驱动型特色制药企业，核心业务涵盖创新药物的研发、生产及商业化，重点攻坚中枢神经系统疾病、代谢性疾病及罕见病等 领域的重大未被满足临床需求。 核心竞争力方面，公司拥有自主研发的创新的药物递送平台，搭建了覆盖研发、生产及销售和营销的一体化内部体系，并组建了丰富的全球产品管线。公司 采用 505(b)(2)注册路径，聚焦特定治疗领域，借助自主构建的全体系研发、生产及商业化能力，实现运营协同效应。 根据弗若斯特沙利文报告，截至2026年1月22日，公司核心产品AUC033产品旗舰的Motpoly XR™是全球第一及唯一经FDA批准的每日一次缓释拉考沙胺， 而GLP-1受体激动剂鼻喷剂的技术水平与研发进度均处于全球前沿。 | 編纂]項下[編纂]數目 : [編纂]股Ｈ股(視乎[編纂] | | --- | | 行使與否而定) | | [編纂]數目 : [編纂]股H股(可予[編纂]) | | [編纂]數目 : [編纂]股H股( ...

Core Viewpoint - The recent conference organized by the Shandong Provincial Geriatric Medicine Society focused on the latest research and future directions in the field of epilepsy, highlighting significant advancements and the establishment of a new leadership team for the Epilepsy Professional Committee [1][7]. Group 1: Conference Highlights - The conference featured a main venue and two sub-venues, gathering numerous renowned experts to discuss the latest research findings and developments in epilepsy [1]. - Notable presentations included 19 keynote reports from leading neurologists, covering topics such as the latest advancements in epilepsy and antiepileptic drugs, and the relationship between epilepsy and cognitive health [2][3]. Group 2: Research and Treatment Advances - The focus of the main venue reports included the latest progress in epilepsy and antiepileptic medications, with discussions on topics like dementia combined with epilepsy and autoimmune encephalitis [2]. - Key findings indicated that valproate remains the first choice for generalized and unclassified epilepsy, while lamotrigine shows comparable efficacy to carbamazepine for focal epilepsy [2]. Group 3: Multidisciplinary Perspectives - Discussions emphasized the close relationship between epilepsy and brain health, noting that epilepsy patients often exhibit poorer cognitive and motor functions compared to non-epileptic individuals [3]. - Research on Lewy body dementia combined with epilepsy highlighted the challenges in clinical diagnosis and the potential value of EEG and MEG in distinguishing it from other types of dementia [3]. Group 4: Future Directions - The new leadership of the Epilepsy Professional Committee aims to enhance individualized treatment, clinical research, and the application of artificial intelligence in epilepsy management [2][7]. - The conference concluded with a commitment to advancing standardized and precise development in epilepsy treatment across Shandong Province, aiming to improve the prevention and treatment of neurological diseases [7].